Reforgene named a 2022 Guangzhou Future Unicorn enterprise
On November 28, the 2022 Guangzhou "Unicorn" innovative enterprise list was announced, and Reforgene was successfully selected as a "Future Unicorn Innovative Enterprise". This is another honor for Reforgene following its selection as a "Guangdong Province Innovative SME" this year. The "Unicorn" innovative enterprise list is guided by the Guangzhou Municipal Science and Technology Bureau and hosted by the Guangzhou Science and Technology Innovation Enterprises Association, aiming to identify innovative enterprises with strong innovation, fast growth and great development potential, cultivate future leading innovative enterprises, and give play to their innovation-leading and demonstration roles.
In recent years, cell and gene therapy has developed rapidly and has become one of the most promising directions in the biomedical field. Reforgene is dedicated to the development of emerging gene editing medicines. With its continuously deepening underlying technology innovation capability and excellent talent team, its first R&D pipeline project achieved milestone progress this year: the IND application for its independently developed beta-thalassemia gene editing medicine RM001 (HBG gene-modified autologous CD34+ hematopoietic stem cell injection) received implied clearance from the NMPA in November this year and will soon enter Phase I clinical trials. The product is a curative medicine for transfusion-dependent beta-thalassemia, and its outstanding early clinical research data were successively presented at the 2022 European Hematology Association (EHA) Congress and the 64th American Society of Hematology (ASH) Annual Meeting in 2022. Reforgene is the only enterprise in China to have presented thalassemia clinical research results at two major international (European/American) hematology conferences.
Reforgene's successful selection into the "Future Unicorn Innovative Enterprise" list shows that its technical capability, innovative achievements, growth and development potential in the gene therapy field have received high recognition and affirmation from the competent authorities and industry experts. Reforgene will take this as an opportunity to focus on innovation and develop into a leading enterprise in gene editing medicines.
About Reforgene
Reforgene Medicine is one of China's leading innovative gene editing drug companies, driven by gene editing technology and dedicated to bringing novel medicines to life. The company has pipeline programs across genetic diseases and complex diseases. Its innovative beta-thalassemia medicine has achieved globally leading clinical progress, and it achieved the world's first cure of an alpha-thalassemia patient.
Media Contact
info@reforgene.com
Forward-Looking Statements
Reports, articles and other content published on this website may contain forward-looking statements relating to Reforgene Medicine ("the Company") and the gene editing and biopharmaceutical industries. These statements may address, among other things, the Company's strategy, research and development, product pipeline and related progress, clinical research, regulatory submissions and approvals, manufacturing, supply and commercialization, collaborations and licensing, as well as industry trends, market size and technological developments. Forward-looking statements can often be identified by words such as "anticipate," "expect," "plan," "intend," "aim," "may," "will," "continue," or similar expressions. They reflect the views of the party making the statement, based on information available as of the date of publication and the expectations and assumptions then held, and are not statements of historical fact.
Statements made or provided by the Company represent the Company's views. Statements made or republished by third-party media, research institutions, experts or other parties represent only the views of those parties and do not necessarily represent the Company's position. Forward-looking statements are subject to known and unknown risks and uncertainties, including but not limited to those relating to research and technology, safety and efficacy, clinical trials, regulatory review and approval, manufacturing and supply, commercialization, collaborations and licensing, intellectual property, competition, laws and regulations, and macroeconomic conditions. Actual results, progress in research or commercialization, and the timing of events may differ materially from those expressed or implied by such statements. Readers should not place undue reliance on forward-looking statements, and past performance is not indicative of future results.
Except as required by law or regulatory requirements, the Company undertakes no obligation to update or revise any forward-looking statements made by it and gives no assurance that they will be realized. Third-party statements are the responsibility of their original publishers. This notice does not constitute investment advice or an offer or solicitation for the subscription, purchase or sale of any securities.